Opendata, web and dolomites

FRAGNET SIGNED

FRAGments training NETwork

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "FRAGNET" data sheet

The following table provides information about the project.

Coordinator
STICHTING VU 

Organization address
address: DE BOELELAAN 1105
city: AMSTERDAM
postcode: 1081 HV
website: www.vu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://fragnet.eu/
 Total cost 3˙842˙481 €
 EC max contribution 3˙842˙481 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2015
 Funding Scheme MSCA-ITN-ETN
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STICHTING VU NL (AMSTERDAM) coordinator 1˙021˙497.00
2    UNIVERSITY OF YORK UK (YORK NORTH YORKSHIRE) participant 819˙863.00
3    UNIVERSITAT DE BARCELONA ES (BARCELONA) participant 495˙745.00
4    TERMESZETTUDOMANYI KUTATOKOZPONT HU (BUDAPEST) participant 447˙827.00
5    VERNALIS (R&D) LIMITED UK (CAMBRIDGE) participant 273˙287.00
6    NOVARTIS PHARMA AG CH (BASEL) participant 265˙226.00
7    BEACTICA THERAPEUTICS AB SE (UPPSALA) participant 263˙659.00
8    ZOBIO BV NL (LEIDEN) participant 255˙374.00
9    24 Media Labs NL (Rotterdam) partner 0.00
10    F. HOFFMANN-LA ROCHE AG CH (BASEL) partner 0.00
11    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) partner 0.00
12    INSTITUT DE RECHERCHES SERVIER FR (SURESNES) partner 0.00
13    IOTA Pharmaceuticals Ltd UK (CAMBRIDGE) partner 0.00

Map

 Project objective

The promise of more efficient lead discovery is fuelling the enthusiasm for fragment-based lead discovery (FBLD). In this approach, highly sensitive biochemical and biophysical screening technologies are being used to detect the low affinity binding of low molecular weight compounds (the so-called fragments) to protein targets that are involved in pathophysiological processes. By investigating the molecular interactions between fragment hit(s) and the target protein, a detailed understanding of the binding event is obtained. This enables the rational and efficient optimisation of the hit fragment. The optimised compounds represent high quality leads for drug development. The necessary FBLD technologies and approaches have emerged mainly from small and specialised biotech companies. At present, FBLD is being adopted throughout pharmaceutical sciences, including by pharmaceutical companies, SMEs and academic research groups. So far, the necessary training that is needed to obtain an holistic view of the possibilities and opportunities that FBLD provides is missing, most likely because the highly multidisciplinary nature of the FBLD work is difficult to capture within one (academic) institute. Therefore, we have established FragNet as a dedicated FBLD training network. The consortium consists of the most prominent pharmaceutical companies, biotech companies and academic groups that have jointly shaped the FBLD research area. FragNet is committed to train 15 ESRs in all facets of FBLD using the combined technologies, skills and knowledge. This will include both research (e.g., technologies on the interface of chemistry and biology) and transferable skill sets (e.g., writing, media training, entrepreneurship and thorough understanding of scientific knowledge transfer). This will enable the ESRs to excel in today’s drug discovery and chemical biology programmes that are performed in public and private organisations in the pharmaceutical sciences.

 Deliverables

List of deliverables.
Open meetings organised Other 2020-04-24 23:22:35
FragNet website Websites, patent fillings, videos etc. 2020-04-09 09:21:05

Take a look to the deliverables list in detail:  detailed list of FRAGNET deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Maciej Majewski, Sergio Ruiz-Carmona, Xavier Barril
An investigation of structural stability in protein-ligand complexes reveals the balance between order and disorder
published pages: , ISSN: 2399-3669, DOI: 10.1038/s42004-019-0205-5
Communications Chemistry 2/1 2020-04-09
2018 Moira M Rachman, Xavier Barril, Roderick E Hubbard
Predicting how drug molecules bind to their protein targets
published pages: 34-39, ISSN: 1471-4892, DOI: 10.1016/j.coph.2018.07.001
Current Opinion in Pharmacology 42 2020-04-09
2018 Péter Ábrányi-Balogh, László Petri, Tímea Imre, Péter Szijj, Andrea Scarpino, Martina Hrast, Ana Mitrović, Urša Pečar Fonovič, Krisztina Németh, Hélène Barreteau, David I. Roper, Kata Horváti, György G. Ferenczy, Janko Kos, Janez Ilaš, Stanislav Gobec, György M. Keserű
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
published pages: 94-107, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2018.10.010
European Journal of Medicinal Chemistry 160 2020-04-09
2018 Angelo K.S. Romasanta, Peter van der Sijde, Iina Hellsten, Roderick E. Hubbard, Gyorgy M. Keseru, Jacqueline van Muijlwijk-Koezen, Iwan J.P. de Esch
When fragments link: a bibliometric perspective on the development of fragment-based drug discovery
published pages: 1596-1609, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2018.05.004
Drug Discovery Today 23/9 2020-04-09
2019 Scarpino, Bajusz, Proj, Gobec, Sosič, Gobec, Ferenczy, Keserű
Discovery of Immunoproteasome Inhibitors Using Large-Scale Covalent Virtual Screening
published pages: 2590, ISSN: 1420-3049, DOI: 10.3390/molecules24142590
Molecules 24/14 2020-04-09
2018 Andrea Scarpino, György G. Ferenczy, György M. Keserű
Comparative Evaluation of Covalent Docking Tools
published pages: 1441-1458, ISSN: 1549-9596, DOI: 10.1021/acs.jcim.8b00228
Journal of Chemical Information and Modeling 58/7 2020-04-09
2018 Aaron Keeley, Péter Ábrányi-Balogh, Martina Hrast, Tímea Imre, Janez Ilaš, Stanislav Gobec, György M. Keserű
Heterocyclic electrophiles as new MurA inhibitors
published pages: 1800184, ISSN: 0365-6233, DOI: 10.1002/ardp.201800184
Archiv der Pharmazie 351/12 2020-04-09
2018 Bas Lamoree, Roderick E. Hubbard
Using Fragment-Based Approaches to Discover New Antibiotics
published pages: 495-510, ISSN: 2472-5552, DOI: 10.1177/2472555218773034
SLAS DISCOVERY: Advancing the Science of Drug Discovery 23/6 2020-04-09
2019 Moira Rachman, Andrea Scarpino, Dávid Bajusz, Gyula Pálfy, István Vida, András Perczel, Xavier Barril, György M. Keserű
DUckCov: a Dynamic Undocking‐Based Virtual Screening Protocol for Covalent Binders
published pages: 1011-1021, ISSN: 1860-7179, DOI: 10.1002/cmdc.201900078
ChemMedChem 14/10 2020-04-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FRAGNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FRAGNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

CALIPER (2019)

Creating Granular Materials Experts by Developing Experimental Calibrations for Computational Methods

Read More  

INFANS (2019)

INtegrating Functional Assessment measures for Neonatal Safeguard

Read More  

synBIOcarb (2018)

Synthetic biology of carbohydrate-binding proteins: engineering protein-carbohydrate interactions for diagnostics and cell targeting

Read More